Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Vomiting 9Nausea 5Breast Neoplasms 4Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Myeloproliferative Disorders 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Inflammatory Breast Neoplasms 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1

Interventions

Dexamethasone 20Melphalan 13Thalidomide 10Bortezomib 10Lenalidomide 8Cyclophosphamide 8Prednisone 6Filgrastim 6Doxorubicin 6Vincristine 5Epoetin Alfa 5pomalidomide 3Zoledronic Acid 3Peripheral Blood Stem Cell Transplantation 3Idarubicin 3carfilzomib 2Vorinostat 2Radiotherapy 2Interferon-alpha 2Granulocyte Colony-Stimulating Factor 2Early Intervention, Educational 2Darbepoetin alfa 2Carmustine 2Calcium Dobesilate 2Busulfan 2valspodar 1sargramostim 1oblimersen 1liposomal doxorubicin 1isatuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms, Plasma Cell × Aprepitant × Clear all
NCT02939287 2024-10-22

Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan

Rush University Medical Center

Phase 3 Completed
52 enrolled 11 charts
Plasma cell

Nausea, Vomiting, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡